-$0.26 Earnings Per Share Expected for Ionis Pharmaceuticals Inc (NASDAQ:IONS) This Quarter

Share on StockTwits

Analysts expect Ionis Pharmaceuticals Inc (NASDAQ:IONS) to post earnings per share (EPS) of ($0.26) for the current quarter, according to Zacks Investment Research. Five analysts have made estimates for Ionis Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.50) and the highest is ($0.07). Ionis Pharmaceuticals posted earnings of ($0.03) per share during the same quarter last year, which suggests a negative year over year growth rate of 766.7%. The business is expected to issue its next earnings report on Tuesday, November 5th.

On average, analysts expect that Ionis Pharmaceuticals will report full year earnings of ($0.07) per share for the current financial year, with EPS estimates ranging from ($0.70) to $0.24. For the next fiscal year, analysts forecast that the firm will post earnings of $0.51 per share, with EPS estimates ranging from ($1.55) to $4.50. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that follow Ionis Pharmaceuticals.

Ionis Pharmaceuticals (NASDAQ:IONS) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.26. The company had revenue of $164.00 million during the quarter, compared to analyst estimates of $145.31 million. Ionis Pharmaceuticals had a net margin of 49.90% and a return on equity of 38.70%. Ionis Pharmaceuticals’s revenue for the quarter was up 39.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.29) EPS.

Several analysts have recently weighed in on IONS shares. TheStreet lowered shares of Ionis Pharmaceuticals from a “b-” rating to a “c” rating in a research note on Thursday, August 8th. Evercore ISI set a $76.00 price objective on shares of Ionis Pharmaceuticals and gave the company a “hold” rating in a research note on Wednesday, August 7th. Piper Jaffray Companies set a $75.00 price objective on shares of Ionis Pharmaceuticals and gave the company a “hold” rating in a research note on Friday, May 24th. Zacks Investment Research lowered shares of Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, July 31st. Finally, Cantor Fitzgerald reiterated a “hold” rating and issued a $68.00 price objective on shares of Ionis Pharmaceuticals in a research note on Wednesday, April 24th. Nine research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. Ionis Pharmaceuticals currently has an average rating of “Hold” and an average target price of $67.78.

Shares of NASDAQ:IONS traded down $1.85 during mid-day trading on Friday, hitting $70.30. The company had a trading volume of 2,117 shares, compared to its average volume of 1,187,611. The firm has a fifty day moving average price of $66.47 and a 200 day moving average price of $68.87. The company has a market capitalization of $9.98 billion, a PE ratio of 23.74 and a beta of 2.07. The company has a debt-to-equity ratio of 0.45, a current ratio of 10.01 and a quick ratio of 9.93. Ionis Pharmaceuticals has a one year low of $43.27 and a one year high of $86.58.

In related news, CEO Stanley T. Crooke sold 10,000 shares of Ionis Pharmaceuticals stock in a transaction on Thursday, July 18th. The shares were sold at an average price of $70.25, for a total value of $702,500.00. Following the completion of the sale, the chief executive officer now owns 79,634 shares of the company’s stock, valued at approximately $5,594,288.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Frederick T. Muto sold 15,000 shares of Ionis Pharmaceuticals stock in a transaction on Tuesday, June 4th. The shares were sold at an average price of $65.29, for a total transaction of $979,350.00. Following the completion of the sale, the director now directly owns 24,794 shares of the company’s stock, valued at approximately $1,618,800.26. The disclosure for this sale can be found here. In the last three months, insiders sold 40,210 shares of company stock valued at $2,650,844. 2.40% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of IONS. Dimensional Fund Advisors LP boosted its holdings in Ionis Pharmaceuticals by 9.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 292,868 shares of the company’s stock worth $15,827,000 after buying an additional 24,169 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Ionis Pharmaceuticals by 6.5% during the fourth quarter. Geode Capital Management LLC now owns 1,341,433 shares of the company’s stock worth $72,517,000 after buying an additional 82,152 shares in the last quarter. Meeder Asset Management Inc. bought a new stake in Ionis Pharmaceuticals during the first quarter worth approximately $184,000. Nisa Investment Advisors LLC boosted its holdings in Ionis Pharmaceuticals by 4.3% during the first quarter. Nisa Investment Advisors LLC now owns 7,676 shares of the company’s stock worth $623,000 after buying an additional 317 shares in the last quarter. Finally, Carroll Financial Associates Inc. boosted its holdings in Ionis Pharmaceuticals by 27.4% during the first quarter. Carroll Financial Associates Inc. now owns 762 shares of the company’s stock worth $61,000 after buying an additional 164 shares in the last quarter. 85.36% of the stock is owned by institutional investors and hedge funds.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

Recommended Story: Hedge Funds – Risk or Reward?

Get a free copy of the Zacks research report on Ionis Pharmaceuticals (IONS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.